Agenus said over half of patients in its Phase 1b MSS metastatic colorectal cancer cohort achieved long-term survival on BOT+BAL, with some still alive and off

BWB News TV • 2026-11-06 14:22 UTC • By Billy Odell Tucker-Robinson

Agenus said over half of patients in its Phase 1b MSS metastatic colorectal cancer cohort achieved long-term survival on BOT+BAL, with some still alive and off therapy. Earlier Phase 2 data showed a 72% complete response rate.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly